SEC Form 4	
------------	--

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

(	ЛС	1B	APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	
--	------------------------------------------------------------------------------------------------------------------------------	--

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

				UI Section	50(II) 0I til	e invesi	ment	Company Act	01 1940							
1. Name and Address of Reporting Person <sup>*</sup> <u>Cooperatieve Gilde Healthcare IV U.A.</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol Inari Medical, Inc. [NARI]							lationship ck all app Direc	,	ting Pers	()		
(Last) NEWTC	(Fii )NLAAN 9	,	/liddle)	3. Date of Earliest Transaction (Month/Day/Year) 12/07/2020							er (give title			(specify		
(Street) UTREC			Zip)	4. If Amen	dment, Date	e of Ori	ginal F	Filed (Month/D	ay/Year		6. Inc Line) X	Form	r Joint/Gro filed by O filed by M on	ne Repo	orting Pers	son
4 714 61	0		I - Non-Deriva			cquire	ed, D	-	-		ciall	-		6.000	anahin la	7. Nature of
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Y	ear) if any	zA. Deemed Execution Date, if any (Month/Day/Year)		action (Instr.				nd 5) Securities Beneficially Owned Following		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Indirect Beneficial Ownership	
						Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			Instr. 4)
Common	Stock		12/07/202	20		s		70,939	D	\$65.	1(1)	7,33	3,069	]		See footnote <sup>(2)</sup>
Common	Stock		12/08/202	20		s		28,677	D	\$65.3	<b>35</b> <sup>(3)</sup>	7,30	4,392	]		See footnote <sup>(2)</sup>
Common	Stock		12/09/202	20		S		36,715	D	\$65.8	38 <sup>(4)</sup>	7,26	7,677	]		See footnote <sup>(2)</sup>
Common	Stock		12/09/202	20		S		112,780	D	<b>\$66.</b> 7	75(5)	7,15	4,897	]		See footnote <sup>(2)</sup>
Common	Stock		12/09/202	20		S		5,729	D	\$67.3	33(6)	7,14	9,168	]		See footnote <sup>(2)</sup>
		Tal	ole II - Derivati (e.g., ρι					sposed of, , convertil				Ownee	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		e (Mo s	iration	ercisable and I Date Iy/Year)	7. Titl Amou Secur Under Deriva Secur 3 and	int of rities rlying ative rity (Inst	De Se (Ir	Price of erivative ecurity 1str. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e ( s   illy   g (	10. Dwnership Form: Direct (D) or Indirect I) (Instr. 4)	Beneficial Ownership (Instr. 4)

Date Exercisable

Code V

(A) (D)

Expiration Date Amount or Number of Shares

Title

1. Name and Address of Reporting Person\*

Cooperatieve Gilde Healthcare IV U.A.

(Last)	(First)	(Middle)	
NEWTONLAA	N 91 3584 BP		
(Street)			
UTRECHT	Р7		
(City)	(State)	(Zip)	
	ess of Reporting Pers		
(Last)	(First)	(Middle)	
(Last) NEWTONLAA	( )	(Middle)	
NEWTONLAA	( )	(Middle)	
. ,	( )	(Middle)	

(City)	(State)	(Zip)
1. Name and Address of <u>Gilde Healthcar</u>		
(Last) NEWTONLAAN 9	(First) 91 3584 BP	(Middle)
(Street) UTRECHT	P7	
(City)	(State)	(Zip)

## Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$65.00 to \$65.58 inclusive. The Reporting Persons undertake to provide to Inari Medical, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

2. All securities reported are held of record by Cooperatieve Gilde Healthcare IV U.A. ("Gilde"). Gilde is managed by Gilde Healthcare IV Management B.V. ("Molangement"). Management is owned by Gilde Healthcare Holding B.V. ("Holding"). Each of Management and Holding may be deemed to have voting, investment and dispositive power with respect to the securities held by Gilde. Each of Management and Holding disclaims beneficial owner ship of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities, except to the extent of their respective pecuniary interests therein.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$65.00 to \$65.73, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$65.21 to \$66.205, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$66.21 to \$67.205, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$67.21 to \$67.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

## **Remarks:**

Cooperatieve Gilde Healthcare IV U.A., By: /s/ Marc Perret, Name: Marc Perret, Title: Managing Director	<u>12/09/2020</u>
<u>Gilde Healthcare IV</u> <u>Management B.V., By: /s/</u> <u>Marc Perret, Name: Marc</u> <u>Perret, Title: Managing</u> <u>Director</u>	<u>12/09/2020</u>
<u>Gilde Healthcare Holding</u> <u>B.V., By: /s/ Marc Perret,</u> <u>Name: Marc Perret, Title:</u> <u>Managing Director</u>	<u>12/09/2020</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.